Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

August 26, 2016 7:00 AM UTC

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks compared with placebo in the study, which enrolled 252 patients with chronic diabetic foot ulcers.

Adocia is halting all of its programs in diabetic foot ulcers, which it called "extremely difficult" to treat. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article